<DOC>
	<DOCNO>NCT02387450</DOCNO>
	<brief_summary>Sildenafil show potential effect vasodilator mechanism inhibitor NO/GMPc Pain activation . The investigator aim estimate benefit sildenafil term morbi-mortality patient arterial claudication multicenter prospective double blind study .</brief_summary>
	<brief_title>Reduced Cardiovascular Morbi-mortality Sildenafil Patients With Arterial Claudication</brief_title>
	<detailed_description>Eligible patient ask participate oral write information . Evaluation walk capacity ( self report treadmill measure ) , co-morbid condition quality life ( WELCH , SF-36 , Edinburg ) perform inclusion , first dose 3 month oral treatment sildenafil 100mg/day placebo inclusion 3 month . Indication revascularisation evaluate 3 month accord symptom walk capacity accord Rutherford classification . Primary endpoint proportion patient show either fatal event ( cardio-vascular noncardiovascular ) hospitalisation non fatal cardiovascular event 6 9 month follow inclusion .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>ABI &lt; 0.90 Vascular type claudication stable walk impairment least 3 month Optimal cardiovasc treatment ( Antiplatelet , HMGCoAInh , ACEInh AT2 inh ) Age &gt; 30 year Refuse participate Administrative protection Severe renal ( clearance &lt; 30 ml/min ) hepatic ( ChildPugh C ) failure</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Claudication</keyword>
	<keyword>Maximal walk distance</keyword>
	<keyword>Morbi-mortality</keyword>
</DOC>